A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess Safety, Tolerability, And Pharmacokinetics Of Multiple Oral Doses Of Pf-06835919 In Healthy Adult Subjects (Part A); And An Open-label Study To Assess Multiple Oral Doses Of Pf-06835919 On Atorvastatin Pharmacokinetics (Part B)
Phase of Trial: Phase I
Latest Information Update: 30 Jun 2017
At a glance
- Drugs PF 06835919 (Primary) ; Atorvastatin
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 19 Jun 2017 Planned End Date changed from 13 Jun 2017 to 1 Jul 2017.
- 19 Jun 2017 Planned primary completion date changed from 13 Jun 2017 to 1 Jul 2017.
- 28 Mar 2017 Planned End Date changed from 4 Jul 2017 to 1 Jun 2017.